Publications dans lesquelles il/elle collabore avec HOURIA BOULAIZ TASSI (12)

2024

  1. Identification of novel biomarkers in the early diagnosis of malignant melanoma by untargeted liquid chromatography coupled to high-resolution mass spectrometry-based metabolomics: a pilot study

    British Journal of Dermatology, Vol. 190, Núm. 5, pp. 740-750

2023

  1. Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma

    Cancers, Vol. 15, Núm. 14

2021

  1. Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma

    Molecular Oncology, Vol. 15, Núm. 2, pp. 407-428

2019

  1. Melanoma cancer stem-like cells: Optimization method for culture, enrichment and maintenance

    Tissue and Cell, Vol. 60, pp. 48-59

2018

  1. Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile

    Cancer Letters, Vol. 429, pp. 78-88

2017

  1. Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism

    Expert Reviews in Molecular Medicine, Vol. 19

  2. Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity

    Scientific Reports, Vol. 7

2016

  1. Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what’s new?

    Expert Opinion on Therapeutic Patents, Vol. 26, Núm. 8, pp. 877-890

2014

  1. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound

    Oncotarget, Vol. 5, Núm. 11, pp. 3590-3606

2013

  1. Cadmium modifies the cell cycle and apoptotic profiles of human breast cancer cells treated with 5-fluorouracil.

    International journal of molecular sciences, Vol. 14, Núm. 8, pp. 16600-16616

2012

  1. Role of cancer stem cells of breast, colon, and melanoma tumors in the response to antitumor therapy

    Stem Cells and Cancer Stem Cells, Volume 3: Stem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury: Volume 3 (Springer Netherlands), pp. 157-171

2011

  1. New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1- benzoxazepin-3-yl]-9H-purine

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 1, pp. 249-258